硫酸普拉睾酮钠治疗阴道萎缩的临床研究进展  

Progress in research of sodium prasterone sulfate in vaginal atrophy

作　　者：覃金玲 孙德友 丁明和 刘蔚 范彦博 夏军 

机构地区：[1]马应龙药业集团股份有限公司,湖北武汉430064

出　　处：《药学实践杂志》2017年第3期205-207,274,共4页Journal of Pharmaceutical Practice

摘　　要：硫酸普拉睾酮钠(dehydroepiandrosterone sulfate,sodium prasterone sulfate,DHEAS)和普拉睾酮(dehydroepiandrosterone,prasterone,DHEA)是人体肾上腺合成分泌的内源性物质,亦是转化为甾体激素包括性激素的前体。按照胞内分泌学说,绝经后女性大多数会产生由于缺乏DHEAS或DHEA引起的内源性性激素缺乏而导致的阴道萎缩性疾病,因此适度补充DHEAS能缓解阴道萎缩的相关症状。多项临床研究表明,DHEAS能有效缓解阴道萎缩的相关症状,长期使用后患者体内的雄激素和雌激素水平仍可维持在正常的生理浓度范围内,因此DHEAS可能会成为未来治疗阴道萎缩症的临床首选药物。Sodium prasterone sulfate （DHEAS） and dehydroepiandrosterone （DHEA） are endogenous steroid compounds, which are synthesized and secreted by adrenal gland.They are the precursors of steroid hormones,including sex hormone.Based on intracrine theory,the majority of postmenopausal women will have vaginal atrophy,which is caused by the absence of endogenous hormones,DHEAS or DHEA.Moderate supplementation of DHEAS can relieve the associated symptoms of vaginal atrophy.Many clinical researches have demonstrated that DHEAS can efficiently alleviate the related symptoms of vaginal atrophy.The concentration of androgen and estrogen in patients with long term use of DHEAS are still in the normal intracrine physiological range.Therefore,DHEAS may become the first drug for the treatment of vaginal atrophy in the future.

关 键 词：普拉睾酮 硫酸普拉睾酮钠 阴道萎缩 

分 类 号：R977.1[医药卫生—药品]